• Pablo Aldaz, Javier Garjón, Guadalupe Beitia, Idoya Beltrán, Julián Librero, Berta Ibáñez, Pilar Arroyo, and Ma José Ariz.
• Navarre Health Service, IdiSNA, Navarra Institute for Health Research, Spain. Electronic address: paldazhe@cfnavarra.es.
• Med Clin (Barc). 2021 Feb 12; 156 (3): 107-111.

ObjectiveTo evaluate the association between use of benzodiazepines and incident dementia.MethodsAnalytical prospective nested case-control study for which the Spanish database for pharmacoepidemiological research in primary care (BIFAP) of the Spanish Agency of Medicines and Medical Devices (AEMPS) was used. A total of 15,212 subjects diagnosed with dementia of the Alzheimer type and 62,397 controls were identified. Exposure was retrieved retrospectively with a 3-year lag time before the index date. Adjusted odd ratios (OR) were calculated.ResultsBenzodiazepines use increased the risk of suffering Alzheimer's disease (OR=1.05, 95% CI, 1.01-1.10). No statistical differences were shown between short-acting and long-acting drugs. The risk is more evident with longer exposure times.ConclusionsThere seems to be a weak association between benzodiazepine use and the development of dementia, the risk increases with greater exposure.Copyright © 2020 Elsevier España, S.L.U. All rights reserved.

20 keywords...

hide…